NOT REPORTED ELSEWHERE
- ▸Wegovy pill sales significantly exceeded estimates in quarterly earnings. — CNBC
- ▸CEO Mike Doustdar expects FDA approval for CagriSema obesity drug by year-end. — Bloomberg Markets
COVERAGE GAP
Novo Nordisk reported earnings above expectations driven by strong Wegovy pill sales.
NOT REPORTED ELSEWHERE